Will Palatin's Phase III Female Sex Endpoint Swap Pass With FDA?
Executive Summary
Palatin plans to file the drug for FDA approval in the second half of 2017, but a change in the co-primary endpoint presents a complication.
You may also be interested in...
AMAG’s Vyleesi Review Offers Lessons On Impact Of Patient Input
US FDA accepted change in Phase III endpoint hierarchy for the hypoactive sexual desire disorder drug based on input from a patient-focused drug development meeting and scientific workshop; bremelanotide review documents advise on use of multiple anchor scales to help interpret meaningfulness of changes in clinical outcome assessment scores.
Keeping Track: FDA OKs AMAG's Vyleesi, But Bronchitol And Quizartinib Draw CRLs
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: A Week Of Calm As Shutdown Drags On
The latest drug development news and highlights from our US FDA Performance Tracker.